Picture of GenFleet Therapeutics (Shanghai) logo

2595 GenFleet Therapeutics (Shanghai) Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly Speculative

Momentum

Relative Strength (%)
1mn/a
3mn/a
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-18.53%
50d MA+1.37%
200d MA+1.37%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS  /

Blurred out image of GenFleet Therapeutics (Shanghai) EPS forecast chart

Profile Summary

GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.

Directors

    Last Annual
    Last Interim
    Incorporated
    August 23rd, 2017
    Public Since
    September 19th, 2025
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    hk flag iconStock Exchange of Hong Kong Limited

    2595 Share Price Performance

    Similar to 2595

    Picture of Abbisko Cayman logo

    Abbisko Cayman

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Akeso logo

    Akeso

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Alphamab Oncology logo

    Alphamab Oncology

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Antengene logo

    Antengene

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ascentage Pharma International logo

    Ascentage Pharma International

    hk flag iconStock Exchange of Hong Kong Limited

    FAQ